Occurrence, course and risk factors of depression during antiviral treatment for chronic hepatitis C in patients with inherited bleeding disorders: a prospective study.
Treatment of hepatitis C virus (HCV) consists of pegylated interferon (IFN)-alpha and ribavirin for 24 or 48 weeks. An important side-effect of IFN-alpha is depression. The occurrence, course and risk factors of depression during antiviral treatment were studied prospectively in HCV patients with inherited bleeding disorders. The Beck Depression Inventory, indicating no, mild, moderate or severe depression, was administered to 47 patients before starting therapy, after 4, 12, 24 and 48 weeks of treatment, and 4 weeks after cessation of therapy. At baseline, five patients (11%) had mild depression. Depression worsened during treatment in three of these patients. In all five patients, (mild) depression persisted 4 weeks after treatment. Of the remaining 42 patients, 23 (55%) developed depression during treatment (14 mild, eight moderate and one severe), mostly (78%) during the first 12 weeks. Four weeks after cessation of treatment, three of 23 patients still had mild depression. The only independent risk factor for development of depression was a history of depression or other psychiatric problems (odds ratio 9.7). For patients with inherited bleeding disorders, depression is a significant, mostly transient, problem during HCV treatment. We recommend close monitoring of patients, especially those with previous psychiatric problems, to ensure adequate detection and treatment of depression during antiviral therapy.
Fransen Van De Putte
D E
DE
Department of Haematology, University Medical Center Utrecht, Utrecht, The Netherlands. d.e.fransenvandeputte@umcutrecht.nl
Fischer
K
K
Posthouwer
D
D
Van Erpecum
K
K
Mauser-Bunschoten
E P
EP
D000293:Adolescent; D000328:Adult; D000368:Aged; D000998:Antiviral Agents / Q000008:administration & dosage / Q000009:adverse effects*; D025861:Blood Coagulation Disorders, Inherited / Q000150:complications / Q000235:genetics / Q000523:psychology*; D003866:Depressive Disorder / Q000139:chemically induced / Q000235:genetics / Q000523:psychology*; D005260:Female; D019698:Hepatitis C, Chronic / Q000188:drug therapy / Q000235:genetics / Q000523:psychology*; D006801:Humans; D007370:Interferon Type I / Q000008:administration & dosage / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D015995:Prevalence; D011446:Prospective Studies; D011994:Recombinant Proteins; D012307:Risk Factors; D011795:Surveys and Questionnaires; D055815:Young Adult
D000998:Antiviral Agents; D007370:Interferon Type I; D011994:Recombinant Proteins